ANX Mast Therapeutics, Inc.

SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that the Company, through its wholly owned subsidiary, ADVENTRX (Europe) Ltd., has received notification from the European Medicines Agency (EMEA) that it has been granted designation as a Small/Medium Enterprise (SME). Implemented in November 2005, the SME program is an initiative by the EMEA that is designed to assist small companies applying for European approval of medicinal products. In addition to financial benefits afforded the designation through lowered or reduced fees, the designation offers participants access to substantial scientific advice during the clinical development and application processes. "We are pleased to have been granted designation as a Small/Medium Enterprise and look forward to the advice and administrative assistance of the EMEA as we continue to pursue clinical development opportunities in the European Union," stated Evan M. Levine, chief executive of ADVENTRX. ADVENTRX (Europe) Ltd. was incorporated in July 2004 in the United Kingdom as a wholly-owned subsidiary of ADVENTRX Pharmaceuticals, Inc., primarily to facilitate conducting clinical trials in the European Union. Additional information on the SME program is available from the EMEA website at: http://www.emea.eu.int/SME/SMErelated.htm. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com/. Forward Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright